ENLV Company Profile and Key Details

The stock is currently mid-range between its 52-week high and low $0.79 and $2.10. With a market capitalization of about $20.37 million, Enlivex Therapeutics Ltd. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.49). Key stats such as the average daily volume over the past year has been around 3.82 million shares, volume is running light vs its 52-week average. Headquartered in Ness Ziona, None, Enlivex Therapeutics Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Oren Hershkovitz, the company employs approximately 71 people and listed since July 31, 2014. Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company.

Enlivex Therapeutics Ltd. has 23.85 million shares outstanding. The public float is 21.32 million shares, elevated short interest at 0.86% of float. This equals 196.54 thousand shares. The short ratio is 0.89 days. Institutional investors hold 11.44% of the float. Insiders own 4.61%.

Enlivex Therapeutics Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.13. This means the shares are trading above this model’s fair value.

ENLV has shown weak momentum, losing -12.94% over the past week and -19.72% over the past quarter, though year-to-date performance is down -28.64%. Short-term trend indicators are bullishly aligned (SMA20 -13.37%, SMA50 -17.42%, SMA200 -22.44%). The stock’s 14-day RSI is 37.47 (weak momentum), while the ATR of 0.1 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -60.24% below its high and over 5.2% above its low. Average 10-day trading volume of 934.56 thousand shares is below the 3-month average of 3.79 million, indicating normal recent market interest.

Enlivex Therapeutics Ltd. generated EPS of -$0.53 over the past year. Five-year average earnings growth is 7.57%. Wall Street analysts project EPS growth of -6.46% annually over the next five years. The latest quarter delivered EPS of -$0.12. The next quarter is forecast at -$0.14. Next year's EPS is expected at $36.76. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 12 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $13.00 to $7.00. The high target offers 1466.27% upside. The low target suggests 743.37% downside. The mean target is $12.00. This offers 1345.78% upside. Enlivex Therapeutics Ltd. earnings surprise history is a mixed track record. The quarter that ended December 05, 2025, missed forecasts by 0.0%. The prior quarter beat by -25.0%. Over the last six quarters, Apple has recorded several small beats. These include -25.0% in November 29, 2024.

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) shares are down -28.64% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Enlivex Therapeutics Ltd. trading at a premium to the broader market with a P/E of -1.58. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.25, suggesting 1487.02% upside. Our AI forecast model points to short-term weakness (-1.78% over two weeks), a medium-term fall (-44.9% over three months), and a longer-term gain (325.2% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Enlivex Therapeutics Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.78%, with price expected at $0.82 by January 02, 2026, within a range of $0.72 to $0.91 3-Month Outlook: Projected fall of -44.9%, reaching $0.46 by March 19, 2026, with a range of $0.40 to $0.52. 1-Year Outlook: Projected gain of 325.2%, with price at $3.55 by December 18, 2026, within a range of $0.00 to $4.55.

Enlivex Therapeutics Ltd. trades at a P/E ratio of -1.58, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.15 suggesting the stock is closer to book value. The P/FCF stands at -1.65, also below market averages.